Drug Interactions between CNJ-016 Injection and rozanolixizumab

MONITOR: Concomitant use of a human neonatal Fc receptor (FcRn) blocker like efgartigimod alfa or rozanolixizumab may decrease the plasma concentrations and therapeutic effects of medications that bind to the FcRn such as immune globulins, monoclonal antibodies, or antibody derivatives containing the human Fc domain of the IgG subclass (e.g., abatacept, aflibercept, asfotase alfa, belatacept, dulaglutide, etanercept, luspatercept, rilonacept, romiplostim, and some recombinant coagulation factors). FcRn blockers target the FcRn, a widely expressed receptor that plays a critical role in recycling and maintaining homeostatic levels of circulating IgG and other antibodies by preventing their cellular degradation.

MANAGEMENT: The potential for reduced effectiveness of medications that bind to the human neonatal Fc receptor should be considered during concomitant treatment with FcRn blockers. When long-term use of such medications is required, consider discontinuing the FcRn blocker and using alternative therapies.

Switch to consumer interaction data